• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

使用感染性增强的纤维镶嵌溶瘤腺病毒对化疗耐药性胰腺癌进行实验性病毒疗法

Experimental virotherapy of chemoresistant pancreatic carcinoma using infectivity-enhanced fiber-mosaic oncolytic adenovirus.

作者信息

Kaliberov S A, Kaliberova L N, Buchsbaum D J, Curiel D T

机构信息

Department of Radiation Oncology, School of Medicine, Washington University in St Louis, St Louis, MO, USA.

Division of Radiation Biology, Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.

出版信息

Cancer Gene Ther. 2014 Jul;21(7):264-74. doi: 10.1038/cgt.2014.26. Epub 2014 Jun 6.

DOI:10.1038/cgt.2014.26
PMID:24903014
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4157623/
Abstract

Pancreatic cancer is a significant clinical problem and novel therapeutic approaches are desperately needed. Recent advances in conditionally replicative adenovirus-based (CRAd) oncolytic virus design allow the application of CRAd vectors as a therapeutic strategy to efficiently target and eradicate chemoresistant pancreatic cancer cells, thereby improving the efficacy of pancreatic cancer treatment. The goal of this study was to construct and validate the efficacy of an infectivity-enhanced, liver-untargeted, tumor-specific CRAd vector. A panel of CRAds has been derived that embodies the C-X-C chemokine receptor type 4 promoter for conditional replication, two-fiber complex mosaicism for targeting expansion and hexon hypervariable region 7 (HVR7) modification for liver untargeting. We evaluated CRAds for cancer virotherapy using a human pancreatic tumor xenograft model. Employment of the fiber mosaic approach improved CRAd replication in pancreatic tumor xenografts. Substitution of the HVR7 of the Ad5 hexon for Ad serotype 3 hexon resulted in decreased liver tropism of systemically administrated CRAd. Obtained data demonstrated that employment of complex mosaicism increased efficacy of the combination of oncolytic virotherapy with chemotherapy in a human pancreatic tumor xenograft model.

摘要

胰腺癌是一个重大的临床问题，迫切需要新的治疗方法。基于条件复制腺病毒（CRAd）的溶瘤病毒设计的最新进展使得CRAd载体能够作为一种治疗策略，有效地靶向并根除化疗耐药的胰腺癌细胞，从而提高胰腺癌治疗的疗效。本研究的目的是构建并验证一种感染性增强、非靶向肝脏、肿瘤特异性的CRAd载体的疗效。已获得一组CRAd，其包含用于条件复制的C-X-C趋化因子受体4型启动子、用于靶向扩展的双纤维复合嵌合以及用于非靶向肝脏的六邻体高变区7（HVR7）修饰。我们使用人胰腺肿瘤异种移植模型评估了CRAd用于癌症病毒治疗的效果。采用纤维嵌合方法可提高CRAd在胰腺肿瘤异种移植中的复制。用Ad血清型3的六邻体替换Ad5六邻体的HVR7可降低全身给药的CRAd对肝脏的嗜性。获得的数据表明，在人胰腺肿瘤异种移植模型中，采用复合嵌合可提高溶瘤病毒治疗与化疗联合治疗的疗效。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ead/4157623/f07cb62b9668/nihms592781f5a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ead/4157623/2266b67e7bef/nihms592781f1a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ead/4157623/b64aa9bd1e33/nihms592781f2a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ead/4157623/9ff76b3e6ab5/nihms592781f3a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ead/4157623/820a90526d17/nihms592781f4a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ead/4157623/f07cb62b9668/nihms592781f5a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ead/4157623/2266b67e7bef/nihms592781f1a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ead/4157623/b64aa9bd1e33/nihms592781f2a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ead/4157623/9ff76b3e6ab5/nihms592781f3a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ead/4157623/820a90526d17/nihms592781f4a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ead/4157623/f07cb62b9668/nihms592781f5a.jpg

相似文献

1
Experimental virotherapy of chemoresistant pancreatic carcinoma using infectivity-enhanced fiber-mosaic oncolytic adenovirus.使用感染性增强的纤维镶嵌溶瘤腺病毒对化疗耐药性胰腺癌进行实验性病毒疗法
Cancer Gene Ther. 2014 Jul;21(7):264-74. doi: 10.1038/cgt.2014.26. Epub 2014 Jun 6.
2
5/35 fiber-modified conditionally replicative adenovirus armed with p53 shows increased tumor-suppressing capacity to breast cancer cells.携带 p53 的 5/35 纤维修饰条件复制型腺病毒对乳腺癌细胞的肿瘤抑制能力增强。
Hum Gene Ther. 2011 Mar;22(3):283-92. doi: 10.1089/hum.2010.058. Epub 2011 Jan 11.
3
Combining high selectivity of replication via CXCR4 promoter with fiber chimerism for effective adenoviral oncolysis in breast cancer.通过CXCR4启动子实现的高复制选择性与纤维嵌合相结合，用于乳腺癌的有效腺病毒溶瘤。
Int J Cancer. 2007 Feb 15;120(4):935-41. doi: 10.1002/ijc.22338.
4
A targeting ligand enhances infectivity and cytotoxicity of an oncolytic adenovirus in human pancreatic cancer tissues.一种靶向配体可增强溶瘤腺病毒在人胰腺癌细胞组织中的感染性和细胞毒性。
J Control Release. 2014 Oct 28;192:284-93. doi: 10.1016/j.jconrel.2014.07.053. Epub 2014 Aug 7.
5
Combination with low-dose gemcitabine and hTERT-promoter-dependent conditionally replicative adenovirus enhances cytotoxicity through their crosstalk mechanisms in pancreatic cancer.联合低剂量吉西他滨和 hTERT 启动子依赖性条件复制腺病毒通过其相互作用机制增强胰腺癌的细胞毒性。
Cancer Lett. 2010 Aug 28;294(2):178-86. doi: 10.1016/j.canlet.2010.01.034. Epub 2010 Feb 16.
6
Virotherapy using a novel chimeric oncolytic adenovirus prolongs survival in a human pancreatic cancer xenograft model.利用新型嵌合溶瘤腺病毒进行病毒治疗可延长人胰腺癌细胞异种移植模型的生存期。
Surgery. 2012 Sep;152(3):441-8. doi: 10.1016/j.surg.2012.05.040. Epub 2012 Jul 31.
7
Optimization of conditionally replicative adenovirus for pancreatic cancer and its evaluation in an orthotopic murine xenograft model.条件性复制腺病毒用于胰腺癌的优化及其在原位小鼠异种移植模型中的评估。
Am J Surg. 2008 Apr;195(4):481-90. doi: 10.1016/j.amjsurg.2007.04.014.
8
Generation of a novel, cyclooxygenase-2-targeted, interferon-expressing, conditionally replicative adenovirus for pancreatic cancer therapy.生成一种新型的、环氧化酶-2 靶向的、表达干扰素的、条件复制型腺病毒，用于胰腺癌治疗。
Am J Surg. 2012 Nov;204(5):741-50. doi: 10.1016/j.amjsurg.2012.02.016. Epub 2012 Jun 29.
9
E1B-55kD-deleted oncolytic adenovirus armed with canstatin gene yields an enhanced anti-tumor efficacy on pancreatic cancer.携带血管生成抑制素基因的E1B-55kD缺失型溶瘤腺病毒对胰腺癌产生增强的抗肿瘤疗效。
Cancer Lett. 2009 Nov 18;285(1):89-98. doi: 10.1016/j.canlet.2009.05.006. Epub 2009 May 28.
10
Defining a murine ovarian cancer model for the evaluation of conditionally-replicative adenovirus (CRAd) virotherapy agents.定义用于评估条件复制型腺病毒（CRAd）病毒疗法制剂的鼠卵巢癌模型。
J Ovarian Res. 2019 Feb 15;12(1):18. doi: 10.1186/s13048-019-0493-5.

引用本文的文献

1
Sendai virus is robust and consistent in delivering genes into human pancreatic cancer cells.仙台病毒在将基因导入人胰腺癌细胞方面表现强劲且稳定。
Heliyon. 2024 Feb 28;10(5):e27221. doi: 10.1016/j.heliyon.2024.e27221. eCollection 2024 Mar 15.
2
Strategies to Develop Potent Oncolytic Viruses and Enhance Their Therapeutic Efficacy.开发强效溶瘤病毒并增强其治疗效果的策略。
JCO Precis Oncol. 2021 Apr 27;5. doi: 10.1200/PO.21.00003. eCollection 2021.
3
Optimization of Early Steps in Oncolytic Adenovirus ONCOS-401 Production in T-175 and HYPERFlasks.

本文引用的文献

1
Cancer statistics, 2014.癌症统计数据，2014 年。
CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29. doi: 10.3322/caac.21208. Epub 2014 Jan 7.
2
Emerging concepts in pancreatic cancer medicine: targeting the tumor stroma.胰腺癌医学的新兴概念：靶向肿瘤基质。
Onco Targets Ther. 2013 Dec 18;7:33-43. doi: 10.2147/OTT.S38111.
3
Retargeting of gene expression using endothelium specific hexon modified adenoviral vector.利用内皮细胞特异性六邻体修饰的腺病毒载体进行基因表达的重定向。
优化 T-175 瓶和 HYPERFlasks 中溶瘤腺病毒 ONCOS-401 生产的早期步骤。
Int J Mol Sci. 2019 Jan 31;20(3):621. doi: 10.3390/ijms20030621.
4
Retargeted oncolytic adenovirus displaying a single variable domain of camelid heavy-chain-only antibody in a fiber protein.靶向重链抗体单一可变区的嵌合重链抗体溶瘤腺病毒
Mol Ther Oncolytics. 2015 Feb 18;2:15001. doi: 10.1038/mto.2015.1. eCollection 2015.
Virology. 2013 Dec;447(1-2):312-25. doi: 10.1016/j.virol.2013.09.020. Epub 2013 Oct 15.
4
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.白蛋白结合型紫杉醇联合吉西他滨治疗胰腺癌可提高生存率。
N Engl J Med. 2013 Oct 31;369(18):1691-703. doi: 10.1056/NEJMoa1304369. Epub 2013 Oct 16.
5
Emerging targets in pancreatic cancer: epithelial-mesenchymal transition and cancer stem cells.胰腺癌的新兴靶点：上皮-间质转化与癌症干细胞
Onco Targets Ther. 2013 Sep 13;6:1261-7. doi: 10.2147/OTT.S34670.
6
Biology and clinical applications of pancreatic cancer stem cells.胰腺癌干细胞的生物学特性及其临床应用
Gastroenterology. 2013 Jun;144(6):1241-8. doi: 10.1053/j.gastro.2013.01.072.
7
Coagulation factor X shields adenovirus type 5 from attack by natural antibodies and complement.凝血因子 X 可保护 5 型腺病毒免受天然抗体和补体的攻击。
Nat Med. 2013 Apr;19(4):452-7. doi: 10.1038/nm.3107. Epub 2013 Mar 24.
8
Viral therapy for pancreatic cancer: tackle the bad guys with poison.胰腺癌的病毒治疗：以毒攻毒。
Cancer Lett. 2013 Jun 1;333(1):1-8. doi: 10.1016/j.canlet.2013.01.035. Epub 2013 Jan 24.
9
Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial.FOLFIRINOX 对比吉西他滨对转移性胰腺癌患者生活质量的影响：来自 PRODIGE 4/ACCORD 11 随机试验的结果。
J Clin Oncol. 2013 Jan 1;31(1):23-9. doi: 10.1200/JCO.2012.44.4869. Epub 2012 Dec 3.
10
Coagulation factor X activates innate immunity to human species C adenovirus.凝血因子 X 激活人体 C 型腺病毒固有免疫。
Science. 2012 Nov 9;338(6108):795-8. doi: 10.1126/science.1226625. Epub 2012 Sep 27.